# Tenaya Therapeutics, Inc.: financial statements, quarterly

TNYA · Nasdaq · CIK 1858848 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tnya.md) · [Financials](/companies/tnya/financials.md) · [Filings](/companies/tnya/filings.md) · [Insiders](/companies/tnya/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tnya/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-209084.md) | [0.0](/filings/0001193125-26-335140.md) | not reported | not reported | [0.2](/filings/0001193125-26-209084.md) | [1.1](/filings/0001193125-26-335140.md) |
| Research and development | $m | [23.1](/filings/0000950170-24-122359.md) | [22.9 d](/filings/0000950170-25-036329.md) | [25.1](/filings/0000950170-25-065741.md) | [22.6](/filings/0000950170-25-104182.md) | [20.4](/filings/0001193125-25-273239.md) | [18.7 d](/filings/0001193125-26-102252.md) | [21.1](/filings/0001193125-26-209084.md) | [17.4](/filings/0001193125-26-335140.md) | [15.4](/filings/0001193125-25-273239.md) | [14.8 d](/filings/0001193125-26-102252.md) | [14.8](/filings/0001193125-26-209084.md) | [16.6](/filings/0001193125-26-335140.md) |
| Operating income | $m | [(30.9)](/filings/0000950170-24-122359.md) | [(31.4) d](/filings/0000950170-25-036329.md) | [(33.8)](/filings/0000950170-25-065741.md) | [(30.8)](/filings/0000950170-25-104182.md) | [(26.7)](/filings/0001193125-25-273239.md) | [(24.7) d](/filings/0001193125-26-102252.md) | [(27.5)](/filings/0001193125-26-209084.md) | [(24.1)](/filings/0001193125-26-335140.md) | [(20.9)](/filings/0001193125-25-273239.md) | [(20.8) d](/filings/0001193125-26-102252.md) | [(20.1)](/filings/0001193125-26-209084.md) | [(44.1)](/filings/0001193125-26-335140.md) |
| Income tax | $m | [0.0 d](/filings/0000950170-24-122359.md) | [0.0 d](/filings/0000950170-25-036329.md) | [0.0](/filings/0000950170-25-065741.md) | [0.0 d](/filings/0000950170-25-104182.md) | [0.0 d](/filings/0001193125-25-273239.md) | [0.0 d](/filings/0001193125-26-102252.md) | [0.0](/filings/0001193125-26-209084.md) | [0.0](/filings/0001193125-26-335140.md) | [0.0 d](/filings/0001193125-25-273239.md) | [0.0 d](/filings/0001193125-26-102252.md) | [0.0](/filings/0001193125-26-209084.md) | [0.0](/filings/0001193125-26-335140.md) |
| Net income | $m | [(29.1)](/filings/0000950170-24-122359.md) | [(29.9) d](/filings/0000950170-25-036329.md) | [(32.2)](/filings/0001193125-25-273239.md) | [(29.4)](/filings/0001193125-25-273239.md) | [(25.6)](/filings/0001193125-25-273239.md) | [(23.8) d](/filings/0001193125-26-102252.md) | [(26.9)](/filings/0001193125-26-335140.md) | [(23.3)](/filings/0001193125-26-335140.md) | [(20.3)](/filings/0001193125-25-273239.md) | [(20.2) d](/filings/0001193125-26-102252.md) | [(19.3)](/filings/0001193125-26-335140.md) | [(43.4)](/filings/0001193125-26-335140.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0000950170-24-122359.md) | not reported | [(0.40)](/filings/0000950170-25-065741.md) | [(0.34)](/filings/0000950170-25-104182.md) | [(0.30)](/filings/0001193125-25-273239.md) | not reported | [(0.24)](/filings/0001193125-26-209084.md) | [(0.14)](/filings/0001193125-26-335140.md) | [(0.12)](/filings/0001193125-25-273239.md) | not reported | [(0.09)](/filings/0001193125-26-209084.md) | [(0.20)](/filings/0001193125-26-335140.md) |
| Basic EPS | $ per share | [(0.39)](/filings/0000950170-24-122359.md) | not reported | [(0.40)](/filings/0000950170-25-065741.md) | [(0.34)](/filings/0000950170-25-104182.md) | [(0.30)](/filings/0001193125-25-273239.md) | not reported | [(0.24)](/filings/0001193125-26-209084.md) | [(0.14)](/filings/0001193125-26-335140.md) | [(0.12)](/filings/0001193125-25-273239.md) | not reported | [(0.09)](/filings/0001193125-26-209084.md) | [(0.20)](/filings/0001193125-26-335140.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [82.2](/filings/0000950170-24-122359.md) | [45.7](/filings/0000950170-25-036329.md) | [59.3](/filings/0000950170-25-065741.md) | [58.1](/filings/0000950170-25-104182.md) | [8.2](/filings/0001193125-25-273239.md) | [4.3](/filings/0001193125-26-102252.md) | [53.8](/filings/0001193125-26-209084.md) | [62.7](/filings/0001193125-26-335140.md) | [56.3](/filings/0001193125-25-273239.md) | [101](/filings/0001193125-26-335140.md) | [80.9](/filings/0001193125-26-209084.md) | [78.1](/filings/0001193125-26-335140.md) |
| Current assets | $m | [127](/filings/0000950170-23-061162.md) | [112](/filings/0000950170-25-036329.md) | [129](/filings/0000950170-24-059576.md) | [105](/filings/0000950170-24-094059.md) | [85.3](/filings/0000950170-24-122359.md) | [67.4](/filings/0001193125-26-102252.md) | [94.5](/filings/0000950170-25-065741.md) | [75.9](/filings/0000950170-25-104182.md) | [61.2](/filings/0001193125-25-273239.md) | [106](/filings/0001193125-26-335140.md) | [96.6](/filings/0001193125-26-209084.md) | [86.0](/filings/0001193125-26-335140.md) |
| Total assets | $m | [193](/filings/0000950170-23-061162.md) | [171](/filings/0000950170-25-036329.md) | [185](/filings/0000950170-24-059576.md) | [163](/filings/0000950170-24-094059.md) | [141](/filings/0000950170-24-122359.md) | [120](/filings/0001193125-26-102252.md) | [144](/filings/0000950170-25-065741.md) | [122](/filings/0000950170-25-104182.md) | [105](/filings/0001193125-25-273239.md) | [147](/filings/0001193125-26-335140.md) | [135](/filings/0001193125-26-209084.md) | [93.5](/filings/0001193125-26-335140.md) |
| Current liabilities | $m | [19.4](/filings/0000950170-23-061162.md) | [22.7](/filings/0000950170-25-036329.md) | [19.2](/filings/0000950170-24-059576.md) | [16.7](/filings/0000950170-24-094059.md) | [16.2](/filings/0000950170-24-122359.md) | [16.0](/filings/0001193125-26-102252.md) | [14.2](/filings/0000950170-25-065741.md) | [12.7](/filings/0000950170-25-104182.md) | [13.2](/filings/0001193125-25-273239.md) | [15.4](/filings/0001193125-26-335140.md) | [16.8](/filings/0001193125-26-209084.md) | [19.0](/filings/0001193125-26-335140.md) |
| Total liabilities | $m | [28.5](/filings/0000950170-23-061162.md) | [31.1](/filings/0000950170-25-036329.md) | [26.7](/filings/0000950170-24-059576.md) | [29.2](/filings/0000950170-24-094059.md) | [28.0](/filings/0000950170-24-122359.md) | [27.1](/filings/0001193125-26-102252.md) | [24.6](/filings/0000950170-25-065741.md) | [22.3](/filings/0000950170-25-104182.md) | [22.1](/filings/0001193125-25-273239.md) | [23.7](/filings/0001193125-26-335140.md) | [28.9](/filings/0001193125-26-209084.md) | [24.1](/filings/0001193125-26-335140.md) |
| Shareholders' equity | $m | [165](/filings/0000950170-24-122359.md) | [139](/filings/0001193125-26-102252.md) | [158](/filings/0001193125-25-273239.md) | [134](/filings/0001193125-25-273239.md) | [113](/filings/0001193125-25-273239.md) | [92.9](/filings/0001193125-26-335140.md) | [119](/filings/0001193125-26-335140.md) | [99.8](/filings/0001193125-26-335140.md) | [82.9](/filings/0001193125-25-273239.md) | [123](/filings/0001193125-26-335140.md) | [106](/filings/0001193125-26-335140.md) | [69.4](/filings/0001193125-26-335140.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(23.6) d](/filings/0000950170-24-122359.md) | [(21.9) d](/filings/0000950170-25-036329.md) | [(28.7)](/filings/0000950170-25-065741.md) | [(23.6) d](/filings/0000950170-25-104182.md) | [(19.8) d](/filings/0001193125-25-273239.md) | [(18.4) d](/filings/0001193125-26-102252.md) | [(23.1)](/filings/0001193125-26-209084.md) | [(15.6) d](/filings/0001193125-26-335140.md) | [(15.6) d](/filings/0001193125-25-273239.md) | [(13.9) d](/filings/0001193125-26-102252.md) | [(19.2)](/filings/0001193125-26-209084.md) | [(3.6) d](/filings/0001193125-26-335140.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122359.md) | [0.4 d](/filings/0000950170-25-036329.md) | [0.6](/filings/0000950170-25-065741.md) | [0.1 d](/filings/0000950170-25-104182.md) | [0.2 d](/filings/0001193125-25-273239.md) | [0.2 d](/filings/0001193125-26-102252.md) | [0.4](/filings/0001193125-26-209084.md) | [0.1 d](/filings/0001193125-26-335140.md) | [0.0 d](/filings/0001193125-25-273239.md) | [0.1 d](/filings/0001193125-26-102252.md) | [0.0](/filings/0001193125-26-209084.md) | [0.2 d](/filings/0001193125-26-335140.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.4](/filings/0000950170-23-061162.md) | [73.1](/filings/0000950170-24-059576.md) | [73.4](/filings/0000950170-24-094059.md) | [73.9](/filings/0000950170-24-122359.md) | [81.0](/filings/0000950170-25-065741.md) | [85.7](/filings/0000950170-25-104182.md) | [86.2](/filings/0001193125-25-273239.md) | [110](/filings/0001193125-26-209084.md) | [163](/filings/0001193125-26-335140.md) | [163](/filings/0001193125-25-273239.md) | [217](/filings/0001193125-26-209084.md) | [218](/filings/0001193125-26-335140.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 224,230,012 at 2026-07-30, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335140.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.